Aerobic glycolysis and tau deposition in preclinical Alzheimer disease

Research of the human brain metabolism in vivo has largely focused on total glucose use (via FDG PET) and, until recently, did not examine the use of glucose outside oxidative phosphorylation which is known as aerobic glycolysis (AG). AG supports important functions including biosynthesis and neuroprotection but decreases dramatically with aging. This multi-tracer PET study evaluated the relationship between AG, total glucose use (CMRGlc), oxygen metabolism (CMRO2), tau and amyloid deposition in 42 individuals, including those at preclinical and symptomatic stages of Alzheimer disease (AD).

Source: Neurobiology of Aging - March 20, 2018 Category: Neuroscience Authors: Andrei G. Vlassenko, Brian A. Gordon, Manu S. Goyal, Yi Su, Tyler M. Blazey, Tony J. Durbin, Lars E. Couture, Jon J. Christensen, Hussain Jafri, John C. Morris, Marcus E. Raichle, Tammie L.-S. Benzinger Source Type: research